ライフサイエンスコーパス: PAF

1 PAF and IPD showed length-dependent somatic and autonomi

2 PAF caused apoptosis in cancer cells resistant to therap

3 PAF did not affect mRNA expression of MyD88, suggesting

4 PAF inhibited LPS-induced phosphorylation of NF-kappaB p

5 PAF is highly expressed in breast cancer cells but not i

6 PAF is implicated in platelet aggregation and activation

7 PAF is rapidly hydrolyzed and degraded to an inactive me

8 PAF is specifically overexpressed in colon cancer cells

9 PAF plays an essential role in UV-induced immune suppres

10 PAF preferentially disrupted the Kindlin-2(+/-) MAECs ba

11 PAF production could be abrogated in triple-negative bre

12 PAF suppressed the expression of DNA methyltransferase (

13 PAF was not associated with increased mortality, HF hosp

14 PAF, histamine, and tryptase levels were measured in blo

15 PAF-1-SMe exhibits a high selectivity for copper over ot

16 PAF-beta-catenin and PAF-PCNA interactions are competiti

17 PAF-treatment had no effect on other acetylating enzymes

18 PAFs for ALRI were 18.0% (95% CI: 8.1, 26.9%) and 18.7%

19 PAFs for NADCs increased during 1995-2009, reaching 10.1

20 PAFs for NADCs were higher in males and increased strong

21 PAFs from AlzGene.org ranged from 2.25% to 37%; those fr

22 PAFs were 2.6% for AIDS-defining cancers (ADCs, includin

23 PAFs were greater in women than in men (5.4% vs 1.9%).

24 r and equals 3.16 x 10(-1) +/- 1.84 x 10(-1) PAF . m(3) . yr . m(-3) (PAF: Potentially Affected Fract

25 e context of Ag(I) ion functionalized PAF-1, PAF-1-SO3Ag.

26 ) +/- 1.84 x 10(-1) PAF . m(3) . yr . m(-3) (PAF: Potentially Affected Fraction of species) indicatin

27 thm or atrial flutter or tachycardia in 59% (PAF), 37% (PeAF), and 19% (LPeAF) of patients, with 15 o

28 freedom from all atrial arrhythmias was 77% (PAF), 75% (PeAF), and 57% (LPeAF).

29 = 0.52; 95% confidence interval, 0.32-0.84; PAF-AH: adjusted odds ratio = 0.63; 95% confidence inter

30 IRM procedure for the entire series was 95% (PAF), 83% (PeAF), and 82% (LPeAF) at 1 year and freedom

31 ministration could augment tumor growth by a PAF-R-dependent process that could be blocked by treatme

32 F by characterizing the PAF acetylhydrolase (PAF-AH) activity and substrate specificity of SsE(M1), S

33 (platelet-activating factor acetylhydrolase [PAF-AH] and superoxide dismutase) were measured from sam

34 main catabolic enzyme (PAF acetylhydrolase; PAF-AH), on U937 cells, in cell free and in intact cell

35 either did not affect or slightly activated PAF-AH activity.

36 gs might subvert host immunity by activating PAF-R.

37 proteins are more potent hydrolases against PAF and have high affinity for PAF.

38 skin sample of controls but was found in all PAF and IPD patients, although with different skin inner

39 Although PAF is not associated with worse outcomes in patients wi

40 In addition to its role in anaphylaxis, PAF has also been implicated as a mediator in both aller

41 at SRC-1/-2-dependent production of SP-A and PAF is crucial for this process.

42 PAF-beta-catenin and PAF-PCNA interactions are competitive, raising the quest

43 bling of alpha-tocopherol concentrations and PAF-AH activity was associated with 50 and 37% decreased

44 platelet-activating factor (PAF) content and PAF receptor expression in human breast cancer cells and

45 ydrolyzing triglycerides, acetyl esters, and PAF indicates that the SsE proteins are more potent hydr

46 Consistent with a role of CKII in FACT and PAF-C function, we show that decreased CKII function in

47 lation, a modification dependent on FACT and PAF-C.

48 a on stroke-related DALYs, risk factors, and PAF from the GBD 2013 Study to estimate the burden of st

49 opherol, within normal reference ranges, and PAF-AH enzymatic activity were associated with decreased

50 ual affinity for histamine H1 -receptors and PAF receptors.

51 sence of differentiated supporting cells and PAFs, suggesting that supporting cells influence the out

52 additive models and compared odds ratios and PAFs between AlzGene.org and Cache County.

53 An anti-PAF receptor Ab led to a significant decrease in miltefo

54 es, further exploration of rupatadine's anti-PAF effects was a logical step forward.

55 ed boundaries of preserved autofluorescence (PAF) and preserved ellipsoid zone (EZ) on FAF and OCT im

56 exposure increases neutrophil activation by PAF, and, taken together with previous observations, dif

57 the enhanced p105 phosphorylation induced by PAF are responsible for down regulation of pro-inflammat

58 mediators and show that they are produced by PAF-AH2, an oxidized-phospholipid-selective phospholipas

59 ylcholine (ChoP) moieties that are shared by PAF and the bacterial cell wall allow S. pneumoniae to l

60 igh BMI and cancer occurrence, we calculated PAFs using BMI estimates from 2002 and used GLOBOCAN2012

61 cetyl-sn-glycerol cholinephosphotransferase (PAF-CPT), and its main catabolic enzyme (PAF acetylhydro

62 Little is known about the combined PAF for these LOAD risk alleles and the utility of these

63 of the polymerase associated factor complex (PAF-C).

64 In mouse models, conditional PAF expression induces mammary ductal hyperplasia.

65 callosal projections from the contralateral PAF.

66 In contrast, PAF inhibition had minimal effects on cytokine levels.

67 rger than that predicted by the conventional PAF calculation.

68 Conversely, PAF, which contains this VASA segment, competitively bou

69 infected withT. cruzi demonstrated decreased PAF production compared to that by cells isolated from w

70 as electrolyte ions endow the nitrogen-doped PAF-Carbon with outstanding electronic performance.

71 roaches reveal that NVP-AUY922 downregulates PAF and decreases breast cancer cell stemness.

72 The proportion of elevated PAF values increased across severity groups (P = .0009).

73 Conversely, ablation of endogenous PAF induces the loss of breast cancer cell stemness.

74 inactive metabolite, lysoPAF, by the enzyme PAF acetylhydrolase, the activity of which has shown to

75 se (PAF-CPT), and its main catabolic enzyme (PAF acetylhydrolase; PAF-AH), on U937 cells, in cell fre

76 his enzyme deprives neutrophils of essential PAF-mediated stimulation.

77 a large population-based sample to estimate PAF and explore the effects of additive and nonadditive

78 To investigate the role of exacerbated PAF signaling in colon cancer, we conducted cell-based a

79 Exogenous PAF inhibited the production of pro-inflammatory cytokin

80 In 21% of eyes PAF and in 43% of eyes preserved EZ had extended beyond

81 FACT) interacts with CKII and may facilitate PAF complex phosphorylation.

82 The platelet-activating factor (PAF) acetylhydrolase SsE produced by GAS is required for

83 tinocyte-derived platelet-activating factor (PAF) activates mast cell migration, in part by upregulat

84 ars, the role of platelet-activating factor (PAF) as a potent mediator involved in the hypersensitivi

85 uercetin, on the platelet activating factor (PAF) biosynthetic enzymes, acetyl-CoA:lyso-PAF acetyltra

86 Platelet-activating factor (PAF) causes wheal and flare responses which are abrogate

87 o an increase in platelet-activating factor (PAF) content and PAF receptor expression in human breast

88 ein-A (SP-A) and platelet-activating factor (PAF) expression, which increases in the developing fetal

89 holipid mediator platelet-activating factor (PAF) increases in LE and that PAF receptor (PAF-r) ablat

90 Platelet-activating factor (PAF) is a naturally occurring phospholipid that mediates

91 Platelet-activating factor (PAF) is a potent lipid mediator that has been implicated

92 Platelet-activating factor (PAF) is a potent phospholipid-derived mediator the centr

93 Platelet-activating factor (PAF) is a powerful proinflammatory mediator that display

94 hanced basal and platelet-activating factor (PAF) or lipopolysaccharide-stimulated vascular leakage c

95 we surmised that platelet-activating factor (PAF) receptor had a significant role in the antileishman

96 cerophospholipid platelet-activating factor (PAF) were markedly reduced in SRC-1/-2-deficient fetal l

97 micry to degrade platelet-activating factor (PAF), a host-derived inflammatory phospholipid.

98 the synthesis of platelet activating factor (PAF), a potent lipid mediator, in human PMNs.

99 matory mediator, platelet-activating factor (PAF), synthesized by activated neutrophils, can induce a

100 of inflammation, platelet-activating factor (PAF).

101 the presence of platelet activating factor (PAF).

102 on molecules and platelet-activating factor (PAF).

103 Here we identify PCNA-associated factor (PAF) as a key molecule that controls cancer cell stemnes

104 subunit of the polymerase-associated factor (PAF) complex and through the ability of Bre1 to catalyze

105 nent of RNA polymerase II-associated factor (PAF) complex, is a novel and important mediator of PRL-3

106 ry regression of peripheral auditory fibers (PAFs) and loss of spiral ganglion neurons (SGNs).

107 ociations of paroxysmal atrial fibrillation (PAF) and persistent atrial fibrillation (PeAF) with surv

108 regulated in paroxysmal atrial fibrillation (PAF) at the level of its R-subunits.

109 treatment of paroxysmal atrial fibrillation (PAF).

110 (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial sites are important; and what the

111 recruitment of the posterior auditory field (PAF), an area that is typically involved in localization

112 lases against PAF and have high affinity for PAF.

113 ings suggest a novel molecular mechanism for PAF, activation of epigenetic modifications.

114 e labeling in cells (SILAC) quantitation for PAF-C phosphorylation from wild-type and CKII temperatur

115 K-1 as the phosphorylation site required for PAF-dependent inhibition of the channel.

116 data are consistent with a pivotal role for PAF as a mediator of anaphylaxis.

117 mice, suggesting an antitumorigenic role for PAF in settings characterized by aberrant function of th

118 support both positive and negative roles for PAF in carcinogenesis.

119 These results indicate significant roles for PAF receptor in the leishmanicidal activity of HPC.

120 to assess the potentially affected fraction (PAF) of species exposed to pH declines.

121 imated the population attributable fraction (PAF) and the years of life gained for these exposures.

122 ction, the population attributable fraction (PAF) calculated conventionally was the same as the PAF c

123 timate the population-attributable fraction (PAF) of stroke-related disability-adjusted life-years (D

124 The population attributable fraction (PAF) was largest for quarrelling often, but the second g

125 nfections (population-attributable fraction [PAF]) and for whom the number needed to treat (NNT) to p

126 estimated population attributable fractions (PAF) for each outcome measure.

127 atios and population attributable fractions (PAF) for late-onset Alzheimer's disease (LOAD) risk loci

128 of MI and population-attributable fractions (PAF) of MI associated with smoking.

129 adjusted population attributable fractions (PAFs) associated with physical inactivity for each disea

130 e derived population attributable fractions (PAFs) using relative risks and BMI estimates in adults b

131 alculated population-attributable fractions (PAFs), estimating the proportion of deaths due to cancer

132 late population attributable risk fractions (PAFs).

133 response-4 (Par-4) amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cance

134 this work, we use porous aromatic framework (PAF) as precursor to produce nitrogen-doped 3D carbon ma

135 three-dimensional porous aromatic framework (PAF) densely functionalized with thioether groups for se

136 mplexation into a porous aromatic framework (PAF), affording significant increase in ethylene uptake

137 ameworks (ZIFs), porous aromatic frameworks (PAFs), the phenomena of temperature-, pressure- and deso

138 ized IPD patients and 14 patients fulfilling PAF diagnostic criteria, and 15 age-matched controls.

139 d in the context of Ag(I) ion functionalized PAF-1, PAF-1-SO3Ag.

140 uggests a new perspective to functionalizing PAFs and other types of advanced porous materials for hi

141 sangial cells are responsible for glomerular PAF generation and, ultimately, are the victims of its e

142 understanding of the mechanisms that govern PAF metabolism and signaling in mesangial cells is impor

143 r quarrelling often, but the second greatest PAF was for the group related to exposure to violence in

144 55 patients (51.9%); 36 patients (34.0%) had PAF and 19 (17.9%) had PeAF.

145 On the other hand, PAF increased p300 histone acetyltransferase expression,

146 gh and high human development indices (HDIs; PAF 5.3% and 4.8%, respectively) than in those with mode

147 control variable group had the third highest PAF, followed by other partner factors.

148 Our findings reveal how PAF-R agonists induced by chemotherapy treatment can pro

149 Importantly, PAF is shown to participate in a broad range of patholog

150 erum PAF levels and a concurrent decrease in PAF acetylhydrolase activity.

151 no intrinsic kinase activity was detected in PAF-C samples.

152 D; (2) neuritic p-syn inclusions differed in PAF and IPD, suggesting a different underlying pathogene

153 antly compromised leishmanicidal function in PAF receptor-deficient mice.

154 change scenarios to estimate the increase in PAF (DeltaPAF) by future ocean acidification.

155 luate altered R-subunit-PP1c interactions in PAF patients.

156 between ethylene molecules and Ag(I) ions in PAF-1-SO3Ag has been evidenced by the high isosteric hea

157 erves, the site of analysis is irrelevant in PAF but it is critical in IPD.

158 M1) but have similar potency with SsE(M1) in PAF hydrolysis.

159 A), and phosphodiesterase type-5A (PDE5A) in PAF patients, with CSDA and PDE5A being novel interactor

160 R-subunits with altered binding to PP1c in PAF were further studied using bioinformatics, Western b

161 ed in the dorsal hippocampus, are reduced in PAF-r antagonist-treated mice.

162 s were found in all analyzed skin samples in PAF but in only 49% of samples with a higher positivity

163 Fluid shear stress exposure increased PAF-induced neutrophil activation in terms of L-selectin

164 UV-induced PAF activates mast cell migration by up-regulating mast

165 UV-induced PAF also activates cell cycle arrest and disrupts DNA re

166 enolic compounds and wine extracts inhibited PAF biosynthetic enzymes, however in higher concentratio

167 hile in higher concentrations only inhibited PAF-CPT.

168 s have demonstrated that rupatadine inhibits PAF effects in nasal airways and produces a greater redu

169 cular dynamic simulation of HPC docking into PAF receptor and by comparison of its leishmanicidal fun

170 l modification analysis of affinity-isolated PAF-C shows extensive CKII phosphorylation of all five s

171 acetyl-CoA:lyso-PAF acetyltransferase (lyso-PAF-AT) and DTT-insensitive CDP-choline 1-alkyl-2-acetyl

172 (PAF) biosynthetic enzymes, acetyl-CoA:lyso-PAF acetyltransferase (lyso-PAF-AT) and DTT-insensitive

173 e same order of magnitude the action of lyso-PAF-AT and of PAF-CPT.

174 The mean PAF areas from 2 independent gradings were 3.720 +/- 3.3

175 S. pneumoniae-mediated PAF deprivation impaired viability, activation, and bact

176 G7), an enzyme that specifically metabolizes PAF and structurally related glycerophospholipids.

177 AGMO modulates PAF production by mouse macrophages, suggesting that it

178 Moreover, PAF expression endows MECs with a self-renewing capacity

179 nitrogen-doped 3D carbon materials, i.e., N-PAF-Carbon, by exposing NH3 media.

180 Moreover, N-PAF-Carbon also possesses large capacitance (385 F g(-1)

181 Moreover, the N-PAF-Carbon displays free from the CO and methanol crosso

182 Actually, the N-PAF-Carbon obtains ~70 mV half-wave potential enhancemen

183 Abrogation of PAF signaling rendered Pce dispensable for S. pneumoniae

184 We suggest that over-activation of PAF-r signaling induces aberrant neuronal plasticity in

185 f magnitude the action of lyso-PAF-AT and of PAF-CPT.

186 therapies for renal patients on the basis of PAF as a drug target.

187 using PAF antagonists or toxin challenge of PAF receptor negative mice reversed or ameliorated many

188 Moreover, the combination of PAF-1-SMe as a material for capture and concentration of

189 this study, we examined the contribution of PAF to the manifestations of lethal toxin challenge in W

190 Genetic or pharmacological deletion of PAF-AH2 reduced the steady-state production of omega-3 e

191 teria included: >/=3 symptomatic episodes of PAF within 6 months of enrollment and failure of >/=1 an

192 Xenopus laevis, ventrovegetal expression of PAF hyperactivates Wnt signaling, developing a secondary

193 In MECs, ectopic expression of PAF induces anchorage-independent cell growth and breast

194 by simulations, indicate the feasibility of PAF-1-SO3Ag for producing 99.95%+ pure C2H4 in a Pressur

195 ate cutaneous immunity via the generation of PAF-R agonists produced through lipid oxidation.

196 Inhibition of PAF activity using PAF antagonists or toxin challenge of

197 Injection of PAF or SP-A into AF at 17.5 days post coitum enhanced ut

198 ses were induced by intradermal injection of PAF, codeine and histamine in 14 healthy volunteers.

199 eural p-syn was a reliable in vivo marker of PAF and IPD; (2) neuritic p-syn inclusions differed in P

200 ion through chromatin via phosphorylation of PAF-C.

201 ked phospholipids that are the precursors of PAF, and global decreases in lipids that were reflective

202 ort the design, synthesis, and properties of PAF-1-SMe, a robust three-dimensional porous aromatic fr

203 The therapeutic role of PAF antagonism has been investigated for several disease

204 Our studies reveal an unexpected role of PAF in regulating Wnt signaling and propose a regulatory

205 rent studies sought to determine the role of PAF-R signaling in CS-mediated immunomodulatory effects.

206 these studies support the continued study of PAF antagonists as potential adjunctive agents in the tr

207 CKII phosphorylation of all five subunits of PAF-C, although CKII subunits were not detected as inter

208 organ that is both a source and a target of PAF.

209 vectors exhibited considerable re-growth of PAFs in the basilar membrane area.

210 comparison of its leishmanicidal function on PAF receptor-deficient macrophages and mice under HPC tr

211 by blocking its heretofore unknown impact on PAF-R activation.

212 be reconciled by injection of either SP-A or PAF into the amnion.

213 on the Ca(2+) flux induced by C5a, fMLF, or PAF.

214 The overall PAF for MSM and transgender women reporting receptive an

215 p15(PAF) is a 12 kDa nuclear protein that acts as a regulato

216 g-cell-nuclear-antigen-associated factor p15(PAF), showing that it is monomeric and intrinsically dis

217 rther validates our structural model for p15(PAF).

218 es as molecular recognition elements for p15(PAF).

219 arly complete NMR backbone assignment of p15(PAF) allowed us to measure 86 N-H(N) residual dipolar co

220 al small angle x-ray scattering curve of p15(PAF) and that computed from a statistical coil ensemble

221 zed by the ubiquitin ligase that targets p15(PAF) for degradation).

222 The p15(PAF) gene is overexpressed in several types of human can

223 d CKII isolated from cells can phosphorylate PAF-C in vitro, whereas no intrinsic kinase activity was

224 ogue in Streptococcus equi, and human plasma PAF-AH (hpPAF-AH).

225 polycyclic diterpene (+)-chatancin, a potent PAF antagonist, is reported.

226 ds with platelet-activating factor receptor (PAF-R) agonist activity.

227 of the platelet-activating factor receptor (PAF-R).

228 (PAF) increases in LE and that PAF receptor (PAF-r) ablation mitigates its progression.

229 their anti-inflammatory activity by reducing PAF levels through modulation of the PAF metabolic enzym

230 ostic measure to predict clinically relevant PAF after PD.

231 age a ChoP-remodeling enzyme (Pce) to remove PAF from the airway.

232 ondom with partners with unknown serostatus (PAF 53%, prevalence 54%, AHR 4.76, 95% CI 1.44-15.71); b

233 enge resulted in transient increase in serum PAF levels and a concurrent decrease in PAF acetylhydrol

234 Significantly, PAF-C purifications combined with stable isotope labelin

235 Center-specific PAF associated with inactivity, body mass index (BMI; in

236 enzyme, GlpQ, to hydrolyze ChoP and subvert PAF function, suggesting that mimicry-driven immune evas

237 ion blocked p300 upregulation and suppressed PAF-induced surface expression of CXCR4.

238 the treatment of drug refractory symptomatic PAF, with no unanticipated device-related adverse events

239 the treatment of drug refractory symptomatic PAF.

240 A total of 242 patients with symptomatic PAF were recruited and randomized as follows: 1) circumf

241 Synthetic PAF-r antagonists, when administered intraperitoneally i

242 also examined whether SsE evolved to target PAF by characterizing the PAF acetylhydrolase (PAF-AH) a

243 gest that the SsE proteins evolved to target PAF for enhancing innate immune evasion and skin invasio

244 vating factor (PAF) increases in LE and that PAF receptor (PAF-r) ablation mitigates its progression.

245 This study provides further evidence that PAF activates epigenetic mechanisms to affect important

246 istamines giving rise to the hypothesis that PAF-induced wheal development is secondary to histamine

247 Recent findings indicate that PAF up-regulates CXCR4 expression via histone acetylatio

248 in immunoprecipitation assays indicated that PAF treatment activated the acetylation of the CXCR4 pro

249 in immunoprecipitation assays indicated that PAF-treatment activated the acetylation of the p21 promo

250 r ethylene/ethane ratio at 296 K reveal that PAF-1-SO3Ag shows exceptionally high ethylene/ethane ads

251 This review focuses on the role that PAF plays specifically in the pathophysiology of the kid

252 Here we show that PAF increases Acetyl-CREB-binding protein (CBP/p300) his

253 Here, we show that PAF-R agonists are produced in melanoma cells by chemoth

254 itive strains (cka1Delta cka2-8) showed that PAF-C phosphorylation at consensus CKII sites is signifi

255 We have shown that PAF production is dependent upon calcium-independent gro

256 We suggest that PAF may serve as an endogenous molecular mediator that l

257 These results clearly suggest that PAF-derived N-doped carbon material is promising metal-f

258 ct mRNA expression of MyD88, suggesting that PAF acts downstream the adaptor.

259 The PAF associated with ever smoking (previous or current) w

260 The PAF level was significantly elevated in proportion to th

261 The PAF of all risk factors increased from 1990 to 2013 (exc

262 The PAF potentiation of IL-10 production was dependent on pr

263 Inhibition of p50 abolished the PAF-induced IL-10 production.

264 hrough its cooperation with RNF20/40 and the PAF complex.

265 two major elongation factors, P-TEFb and the PAF complex.

266 alculated conventionally was the same as the PAF calculated directly from the models.

267 using a Poisson model, and we calculated the PAF and NNT for risk behaviour subgroups.

268 evolved to target PAF by characterizing the PAF acetylhydrolase (PAF-AH) activity and substrate spec

269 R 4.76, 95% CI 1.44-15.71); by contrast, the PAF for receptive anal intercourse without a condom with

270 low-income and middle-income countries, the PAF of behavioural risk clusters in males was greater th

271 We aimed to estimate the PAF and NNT of participants in the iPrEx (Pre-Exposure P

272 creasing number of species available for the PAF (pH10 standard deviation was 0.20, 0.21, and 0.33 fo

273 ses to LPS and highlighted functions for the PAF complex and oligosaccharyltransferase (OST) complex.

274 tinylated dextran amine was deposited in the PAF unilaterally, to label cortical and thalamic afferen

275 infection or increasing infectiousness), the PAF calculated directly from the models was much larger

276 hat compared with wild-type macrophages, the PAF receptor-deficient macrophages showed 1) reduced bin

277 clonal antibody (MAb), 2B11, neutralized the PAF acetylhydrolase activity of SsE.

278 Consideration of the PAF and NNT can aid in discussion of the benefits and ri

279 MPASS but rather works in the context of the PAF and Rad6/Bre1 complexes.

280 Loss of Leo1 leads to destabilization of the PAF complex and downregulation of SOX2 and SOX4, potent

281 educing PAF levels through modulation of the PAF metabolic enzymes.

282 Structural characterization of the PAF-R agonists induced revealed multiple oxidized glycer

283 ur results unveil an unsuspected role of the PAF-Wnt signalling axis in modulating cell plasticity, w

284 ages, suggesting that it may act through the PAF/PAF receptor pathway previously shown to have anti-L

285 Thus, the PAF-AH2-omega-3 epoxide-Srcin1 axis presents new potenti

286 the thalamic and cortical projections to the PAF in hearing cats and those with early- and late-onset

287 these minor differences, connectivity to the PAF was largely similar between groups, with the princip

288 e they regulated the nucleolar levels of the PAFs.

289 Then, PAF recruits EZH2 to the beta-catenin transcriptional co

290 Inhibition of PAF activity using PAF antagonists or toxin challenge of PAF receptor negat

291 Neutrophil activation via PAF was found to correlate with fluid shear stress expos

292 How well PAF correlates with severity relative to histamine or tr

293 XCR4 expression; therefore, we asked whether PAF activates epigenetic mechanisms in mast cells.

294 and microenvironment seem to define whether PAF has pro- or anticarcinogenic effects.

295 osclerotic disease, and malignancy, in which PAF signaling has an established role.

296 which has shown to correlate inversely with PAF levels and predispose to severe anaphylaxis.

297 nts (mean age 59 +/- 12 years, 79% men) with PAF (37%), PeAF (31%), or LPeAF (32%).

298 revalences of POCD were 13% in patients with PAF, 20% in patients with PeAF, 3% in patients with SVT,

299 with either PVI or GP alone in patients with PAF.

300 Human mast cells were treated with PAF, and the effect on DNA methylation and/or acetylatio